Pharmaceutical Business review

Biolase reduces workforce by 20%

Internationally, the company is in the process of restructuring its sales and marketing business units in four countries in order to eliminate direct selling infrastructure costs. The company reported that historically, the four foreign subsidiaries have not reached the breakeven sales points and were losing a total of about $4 million per year.

In New Zealand and Australia, the company has signed a distribution agreement with the foreign subsidiaries of Henry Schein, its exclusive North American distribution partner. It is also seeking similar partnerships in Germany and Spain with the goal of maintaining a high level of sales and customer support. According to the company, the total workforce reduction since last fall is approximately 37%.